Remove 2022 Remove Brands Remove Innovation Remove Tourism
article thumbnail

Mainland China’s regulatory evolution brings greater access to novel drugs

Clarivate

Hemophagocytic lymphohistiocytosis (HLH) Emapalumab Gamifant Swedish Orphan Biovitrum AB 2022 Patients with refractory or relapsed HLH HLH is an extremely rare, highly progressive hyperinflammatory disorder. No drugs are approved for the treatment of HLH and mortality rates are high (30-40%).

Tourism 52
article thumbnail

The Hospitality Industry in a Time of Social Distancing: Threat and Opportunity

Maru Group

Consumer spending on travel and tourism, hotel rooms, conferences and weddings has plummeted by two thirds. McKinsey’s modeling suggests it will be 2022 or even 2023 before demand recovers. For the buffet, changes cut to the heart of their brand. “’All That’s what is at risk right now, the essence of the experience.”